| Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (NCT05334329) | University of California, Irvine | 2022-07-20 |
| Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (NCT05440916) | University Medical Centre Maribor | 2022-07-14 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (NCT05098210) | Fred Hutchinson Cancer Center | 2022-06-09 |
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations (NCT05256290) | Black Diamond Therapeutics, Inc. | 2022-03-31 |
| Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC (NCT04925986) | Sarah Goldberg | 2022-02-10 |
| Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (NCT04780568) | Ohio State University Comprehensive Cancer Center | 2022-01-18 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (NCT04919369) | Dwight Owen | 2021-10-18 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (NCT04940299) | M.D. Anderson Cancer Center | 2021-09-23 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery (NCT04588246) | NRG Oncology | 2021-08-05 |
| Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (NCT04639245) | Fred Hutchinson Cancer Center | 2021-07-19 |
| Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer (NCT05045404) | M.D. Anderson Cancer Center | 2021-06-16 |
| Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer (NCT04837716) | M.D. Anderson Cancer Center | 2021-03-18 |
| MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer (NCT04762199) | Emory University | 2021-02-24 |
| Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer (NCT04751747) | Rutgers, The State University of New Jersey | 2021-02-11 |
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (NCT04285671) | Jonsson Comprehensive Cancer Center | 2021-01-29 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (NCT04789668) | M.D. Anderson Cancer Center | 2021-01-15 |
| Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer (NCT04533451) | Alliance for Clinical Trials in Oncology | 2020-11-16 |
| Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer (NCT04250545) | National Cancer Institute (NCI) | 2020-10-26 |
| Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer (NCT03831932) | National Cancer Institute (NCI) | 2020-03-16 |
| Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC (NCT04227028) | City of Hope Medical Center | 2020-03-09 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy (NCT04186988) | University of California, Davis | 2019-11-05 |
| PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer (NCT04151940) | University of Washington | 2019-09-26 |
| Insomnia in Patients With Metastatic Lung Cancer (NCT06472804) | Mayo Clinic | 2019-06-19 |
| Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer (NCT03600701) | National Cancer Institute (NCI) | 2018-11-29 |
| Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (NCT02971501) | National Cancer Institute (NCI) | 2018-06-27 |
| Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease (NCT03025256) | M.D. Anderson Cancer Center | 2018-05-02 |
| Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced (NCT03225664) | M.D. Anderson Cancer Center | 2018-02-03 |
| Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (NCT02888743) | National Cancer Institute (NCI) | 2017-08-14 |
| Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors (NCT02589522) | National Cancer Institute (NCI) | 2017-05-22 |
| Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer (NCT02503722) | National Cancer Institute (NCI) | 2017-03-23 |
| CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (NCT02955290) | Roswell Park Cancer Institute | 2016-12-22 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCT02498613) | National Cancer Institute (NCI) | 2016-08-31 |
| Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663) | National Cancer Institute (NCI) | 2016-05-11 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866) | National Cancer Institute (NCI) | 2016-04-04 |
| Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer (NCT02444741) | M.D. Anderson Cancer Center | 2015-09-17 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |